Voltage-Sensing Domain of the Third Repeat of Human Skeletal Muscle NaV1.4 Channel As a New Target for Spider Gating Modifier Toxins.

NMR spectroscopy cell-free protein synthesis gating modifier toxins ligand–receptor interaction sodium channels

Journal

Acta naturae
ISSN: 2075-8251
Titre abrégé: Acta Naturae
Pays: Russia (Federation)
ID NLM: 101525823

Informations de publication

Date de publication:
Historique:
entrez: 7 5 2021
pubmed: 8 5 2021
medline: 8 5 2021
Statut: ppublish

Résumé

Voltage-gated sodium channels (NaV) have a modular architecture and contain five membrane domains. The central pore domain is responsible for ion conduction and contains a selectivity filter, while the four peripheral voltage-sensing domains (VSD-I/IV) are responsible for activation and rapid inactivation of the channel. "Gating modifier" toxins from arthropod venoms interact with VSDs, influencing the activation and/or inactivation of the channel, and may serve as prototypes of new drugs for the treatment of various channelopathies and pain syndromes. The toxin-binding sites located on VSD-I, II and IV of mammalian NaV channels have been previously described. In this work, using the example of the Hm-3 toxin from the crab spider

Identifiants

pubmed: 33959393
doi: 10.32607/actanaturae.11279
pmc: PMC8084291
doi:

Types de publication

Journal Article

Langues

eng

Pagination

134-139

Informations de copyright

Copyright ® 2021 National Research University Higher School of Economics.

Références

Nature. 2007 Nov 15;450(7168):370-5
pubmed: 18004375
Proc Natl Acad Sci U S A. 2018 Apr 24;115(17):4495-4500
pubmed: 29636418
Handb Exp Pharmacol. 2018;246:309-330
pubmed: 28939973
Front Pharmacol. 2011 Nov 09;2:71
pubmed: 22084632
J Physiol. 2012 Jun 1;590(11):2577-89
pubmed: 22473783
Science. 2018 Oct 19;362(6412):
pubmed: 30190309
Annu Rev Physiol. 2015;77:481-504
pubmed: 25668026
Drug Discov Today. 2019 Jul;24(7):1389-1397
pubmed: 31129313
Nature. 2008 Nov 13;456(7219):202-8
pubmed: 19005548
J Biol Chem. 2015 Jan 2;290(1):492-504
pubmed: 25352595
Front Pharmacol. 2019 Sep 04;10:953
pubmed: 31555136
Science. 2019 Mar 22;363(6433):1303-1308
pubmed: 30765606
J Am Chem Soc. 2010 Apr 28;132(16):5630-7
pubmed: 20356312

Auteurs

M Yu Myshkin (MY)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997 Russia.

A S Paramonov (AS)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997 Russia.

D S Kulbatskii (DS)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997 Russia.

E A Surkova (EA)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997 Russia.

A A Berkut (AA)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997 Russia.

A A Vassilevski (AA)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997 Russia.

E N Lyukmanova (EN)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997 Russia.
Biological Faculty, Lomonosov Moscow State University, Moscow, 119234 Russia.

M P Kirpichnikov (MP)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997 Russia.
Biological Faculty, Lomonosov Moscow State University, Moscow, 119234 Russia.

Z O Shenkarev (ZO)

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, 117997 Russia.

Classifications MeSH